These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29300496)

  • 1. Hepcare Europe - bridging the gap in the treatment of hepatitis C: study protocol.
    Swan D; Cullen W; Macias J; Oprea C; Story A; Surey J; Vickerman P; Lambert JS
    Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):303-314. PubMed ID: 29300496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring and understanding HCV patient journeys- HEPCARE Europe project.
    Glaspy S; Avramovic G; McHugh T; Oprea C; Surey J; Ianache I; Macías J; Story A; Cullen W; Lambert JS
    BMC Infect Dis; 2021 Mar; 21(1):239. PubMed ID: 33673828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HepCare Ireland-a service innovation project.
    Connolly SP; Avramovic G; Cullen W; McHugh T; O'Connor E; Mc Combe G; Crowley D; Naughton AM; Horan A; Lambert JS
    Ir J Med Sci; 2021 May; 190(2):587-595. PubMed ID: 32761548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
    Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
    Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.
    Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L
    Int J Drug Policy; 2017 Sep; 47():77-85. PubMed ID: 28578863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England.
    Ward Z; Reynolds R; Campbell L; Martin NK; Harrison G; Irving W; Hickman M; Vickerman P
    Addiction; 2020 Aug; 115(8):1509-1521. PubMed ID: 31984606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).
    Fadnes LT; Aas CF; Vold JH; Ohldieck C; Leiva RA; Chalabianloo F; Skurtveit S; Lygren OJ; Dalgård O; Vickerman P; Midgard H; Løberg EM; Johansson KA;
    BMC Infect Dis; 2019 Nov; 19(1):943. PubMed ID: 31703669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands.
    Helsper CW; Janssen MP; van Essen GA; Croes EA; van der Veen C; de Wit AG; de Wit NJ
    Int J Drug Policy; 2017 Sep; 47():117-125. PubMed ID: 28826994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Beyond the willing & the waiting' - The role of peer-based approaches in hepatitis C diagnosis & treatment.
    Henderson C; Madden A; Kelsall J
    Int J Drug Policy; 2017 Dec; 50():111-115. PubMed ID: 28927831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review.
    Bajis S; Dore GJ; Hajarizadeh B; Cunningham EB; Maher L; Grebely J
    Int J Drug Policy; 2017 Sep; 47():34-46. PubMed ID: 28797498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for the management of hepatitis C virus infection among people who inject drugs.
    Robaeys G; Grebely J; Mauss S; Bruggmann P; Moussalli J; De Gottardi A; Swan T; Arain A; Kautz A; Stöver H; Wedemeyer H; Schaefer M; Taylor L; Backmund M; Dalgard O; Prins M; Dore GJ;
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S129-37. PubMed ID: 23884061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating hepatitis C care for at-risk groups (HepLink): baseline data from a multicentre feasibility study in primary and community care.
    Nic An Riogh E; Swan D; McCombe G; O'Connor E; Avramovic G; Macías J; Oprea C; Story A; Surey J; Vickerman P; Ward Z; Lambert JS; Tinago W; Ianache I; Iglesias M; Cullen W
    J Antimicrob Chemother; 2019 Nov; 74(Suppl 5):v31-v38. PubMed ID: 31782502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HepCare Europe-A service innovation project. HepCheck: Characteristics of the patient population with active infection as defined by HCV RNA.
    Avramovic G; Oprea C; Surey J; Story A; Macías J; Cullen W; Iglesias M; Mc Hugh T; Crowley D; Naughton AM; Horan A; Ianache I; Lazar S; Popa I; Menezes D; Lambert JS
    Int J Infect Dis; 2020 Feb; 91():246-251. PubMed ID: 31785401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs.
    Stephens DB; Young AM; Havens JR
    Int J Drug Policy; 2017 Sep; 47():86-94. PubMed ID: 28648353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries.
    Maticic M; Videcnik Zorman J; Gregorcic S; Schatz E; Lazarus JV
    BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S14. PubMed ID: 25252635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection.
    Artenie AA; Zang G; Daniel M; Fortier E; Jutras-Aswad D; Puzhko S; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():239-243. PubMed ID: 28587944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
    Bruggmann P; Grebely J
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation and evaluation of an educational intervention for safer injection in people who inject drugs in Europe: a multi-country mixed-methods study.
    Roux P; Donadille C; Magen C; Schatz E; Stranz R; Curado A; Tsiakou T; Verdes L; Aleksova A; Carrieri P; Mezaache S; Charif Ali B;
    Int J Drug Policy; 2021 Jan; 87():102992. PubMed ID: 33096364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain.
    Ryan P; Valencia J; Cuevas G; Torres-Macho J; Troya J; Pueyo Á; José Muñoz-Gómez M; Muñoz-Rivas N; Vázquez-Morón S; Martinez I; Lazarus JV; Resino S
    Int J Drug Policy; 2021 Oct; 96():103424. PubMed ID: 34429222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introducing hepatitis C virus healthcare pathways in addiction care in the Netherlands with a Breakthrough project: a mixed method study.
    Kracht PAM; de Gee EA; van der Poel A; Verhagen MAMT; Hoepelman AIM; Croes EA; Arends JE
    Harm Reduct J; 2019 Jul; 16(1):45. PubMed ID: 31307470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.